Novo Nordisk has confirmed receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that a TV advertisement for its Wegovy weight-loss pill broadcast in the U.S. is considered "false or misleading." According to the letter, the FDA identified phrases such as "live lighter" and "a way forward" that might lead viewers to believe Wegovy is superior to other weight-loss medications. Novo has acknowledged the feedback and is taking it seriously, signaling its commitment to regulatory standards in marketing its products.

In response to the FDA's concerns, Novo Nordisk is currently drafting a reply to address the issues raised regarding the advertisement's content. The company has noted that it is taking the FDA's regulatory feedback seriously to ensure compliance and to clarify any misinterpretations that may have arisen from the ad. This proactive approach is crucial for maintaining trust with both regulatory authorities and consumers in the highly scrutinized pharmaceutical industry.

The FDA has stipulated that Novo has 15 business days from the date of the letter to provide a response, highlighting the urgency of the matter. As Wegovy has been a significant product for Novo, both in terms of revenue and impact within the competitive weight-loss medication market, how the company handles this situation could have broader implications for its marketing strategies and regulatory compliance moving forward.